Elkfork Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Elkfork Partners’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$27K	Hold	3,584	–	–	﹤0.01%	1015
2019 Q2	$33K	Hold	3,584	–	–	﹤0.01%	1012
2019 Q1	$19K	Sell	3,584 -700	-16%	-$3.99K	﹤0.01%	1018
2018 Q4	$19K	Buy	+4,284	New	+$23.5K	﹤0.01%	980
2018 Q3	–	Sell	-47,656	Closed	-$335K	–	1026
2018 Q2	$335K	Buy	47,656 +2,380	+5%	+$23.4K	0.01%	645
2018 Q1	$644K	Hold	45,276	–	–	0.02%	458
2017 Q4	$397K	Sell	45,276 -5,012	-10%	-$49.6K	0.01%	604
2017 Q3	$588K	Buy	50,288 +3,164	+7%	+$38.8K	0.02%	449
2017 Q2	$658K	Buy	47,124 +18,704	+66%	+$214K	0.02%	421
2017 Q1	$390K	Hold	28,420	–	–	0.01%	496
2016 Q4	$204K	Buy	+28,420	New	+$311K	0.01%	568

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Elkfork Partners's SNDX Position: Q3 2019 in Review

Elkfork Partners held its Syndax Pharmaceuticals (SNDX) position steady in Q3 2019 at 3,584 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #1015.

Elkfork Partners first reported a position in SNDX in Q4 2016 and has held it in 11 quarters since. The position peaked at $658K in Q2 2017. 72 funds tracked by Wall St. Rank hold SNDX as of Q3 2019.

Elkfork Partners held 3,584 shares of Syndax Pharmaceuticals worth $27K as of Q3 2019.
Elkfork Partners left its Syndax Pharmaceuticals share count unchanged in Q3 2019.
Syndax Pharmaceuticals made up ﹤0.01% of Elkfork Partners's portfolio in Q3 2019, its #1015 holding.
Elkfork Partners first reported a position in Syndax Pharmaceuticals in Q4 2016 and has held it in 11 quarters since.
Elkfork Partners's Syndax Pharmaceuticals position peaked at $658K in Q2 2017.
72 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.